Request a copy

Full Text

• Camm, A.J., Kirchhof, P., Lip, G.Y., Schotten, U., Savelieva, I., Ernst, S., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (2010) Europace, 12, pp. 1360-1420
• Connolly, S.J., Eikelboom, J., Joyner, C., Diener, H.C., Hart, R., Golitsyn, S., AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation (2011) N Engl J Med, 364, pp. 806-817
• Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., ROCKET AF Investigators. Rivaroxaban vs. warfarin in nonvalvular atrial fibrillation (2011) N Engl J Med, 365, pp. 883-891
• Granger, C.B., Alexander, J.H., McMurray, J.J., Lopes, R.D., Hylek, E.M., Hanna, M., ARISTOTLE Committees and Investigators. Apixaban vs. warfarin in patients with atrial fibrillation (2011) N Engl J Med, 365, pp. 981-992
• Connolly, S.J., Camm, A.J., Halperin, J.L., Joyner, C., Alings, M., Amerena, J., PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation (2011) N Engl J Med, 365, pp. 2268-2276
• Wann, L.S., Curtis, A.B., January, C.T., Ellenbogen, K.A., Lowe, J.E., Estes III, N.A., ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) Circulation, 123, pp. 104-123
• Wann, L.S., Curtis, A.B., Ellenbogen, K.A., Estes III, N.A., Ezekowitz, M.D., Jackman, W.M., American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) Circulation, 123, pp. 1144-1150
• You, J.J., Singer, D.E., Howard, P.A., Lane, D.A., Eckman, M.H., Fang, M.C., American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (2012) Chest, 141. , pp. e531S-75S
• Skanes, A.C., Healey, J.S., Cairns, J.A., Dorian, P., Gillis, A.M., McMurtry, M.S., Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012. Update of the Canadian Cardiovascular Society Atrial fibrillation Guidelines: Recommendations for stroke prevention and rate/rhythm control (2012) Can J Cardiol, 28, pp. 125-136
• Lip, G.Y., Tse, H.F., Lane, D.A., Atrial fibrillation (2012) Lancet, 379, pp. 648-661
• Kirchhof, P., Lip, G.Y., Van Gelder, I.C., Bax, J., Hylek, E., Kaab, S., Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference (2012) Europace, 14, pp. 8-27
• Healey, J.S., Connolly, S.J., Gold, M.R., Israel, C.W., Van Gelder, I.C., Capucci, A., ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke (2012) N Engl J Med, 366, pp. 120-129
• Binici, Z., Intzilakis, T., Nielsen, O.W., Kober, L., Sajadieh, A., Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke (2010) Circulation, 121, pp. 1904-1911
• Fitzmaurice, D.A., Hobbs, F.D., Jowett, S., Mant, J., Murray, E.T., Holder, R., Screening vs. routine practice in detection of atrial fibrillation in patients aged 65 or over: Cluster randomised controlled trial (2007) BMJ, 335, p. 383
• Hobbs, F.D., Fitzmaurice, D.A., Mant, J., Murray, E., Jowett, S., Bryan, S., A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) vs. routine practice for the detection of atrial fibrillation in people aged 65 and over. the SAFE study (2005) Health Technol Assess., 9, pp. iii-iv. , ix-x, 1-74
• Lip, G., What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation? (2012) J R Coll Physicians Edinb, 42 (SUPPL. 18), pp. 35-44
• Lip, G.Y., Stroke in atrial fibrillation: Epidemiology and thromboprophylaxis (2011) J Thromb Haemost, 9 (SUPPL. 1), pp. 344-351
• Wilke, T., Groth, A., Mueller, S., Pfannkuche, M., Verheyen, F., Linder, R., Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients (2012) Thromb Haemost, 107, pp. 1053-1065
• Kirchhof, P., Nabauer, M., Gerth, A., Limbourg, T., Lewalter, T., Goette, A., AFNET registry investigators. Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions (2011) Thromb Haemost, 105, pp. 1010-1023
• Lip, G.Y., The role of aspirin for stroke prevention in atrial fibrillation (2011) Nat Rev Cardiol, 8, pp. 602-606
• Olesen, J.B., Lip, G.Y., Lindhardsen, J., Lane, D.A., Ahlehoff, O., Hansen, M.L., Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study (2011) Thromb Haemost, 106, pp. 739-749
• Ogilvie, I.M., Welner, S.A., Cowell, W., Lip, G.Y., Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients (2011) Thromb Haemost, 106, pp. 34-44
• Mant, J., Hobbs, F.R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G.Y., Murray, E., Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial (2007) Lancet, 370 (9586), pp. 493-503. , DOI 10.1016/S0140-6736(07)61233-1, PII S0140673607612331
• Rash, A., Downes, T., Portner, R., Yeo, W.W., Morgan, N., Channer, K.S., A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO) (2007) Age and Ageing, 36 (2), pp. 151-156. , DOI 10.1093/ageing/afl129
• Friberg, L., Rosenqvist, M., Lip, G.Y., Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation Cohort study (2012) Eur Heart J, 33, pp. 1500-1510
• Connolly, S.J., Pogue, J., Hart, R.G., Hohnloser, S.H., Pfeffer, M., Chrolavicius, S., Effect of clopidogrel added to aspirin in patients with atrial fibrillation (2009) N Engl J Med, 360, pp. 2066-2078
• Seshasai, S.R., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Erqou, S., Sattar, N., Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials (2012) Arch Intern Med, 172, pp. 209-216
• De Caterina, R., Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., Coordinating Committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper (2012) J Am Coll Cardiol, 59, pp. 1413-1425
• Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W., Radford, M.J., Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation (2001) Journal of the American Medical Association, 285 (22), pp. 2864-2870
• Karthikeyan, G., Eikelboom, J.W., The CHADS2 score for stroke risk stratification in atrial fibrillation - Friend or foe? (2010) Thromb Haemost, 104, pp. 45-48
• Keogh, C., Wallace, E., Dillon, C., Dimitrov, B.D., Fahey, T., Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis (2011) Thromb Haemost, 106, pp. 528-538
• Lin, L.Y., Lee, C.H., Yu, C.C., Tsai, C.T., Lai, L.P., Hwang, J.J., Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation - A nationwide database analysis (2011) Atherosclerosis, 217, pp. 292-295
• Olesen, J.B., Fauchier, L., Lane, D.A., Taillandier, S., Lip, G.Y., Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project (2012) Chest, 141, pp. 147-153
• Olesen, J.B., Lip, G.Y., Lane, D.A., Køber, L., Hansen, M.L., Karasoy, D., Vascular disease and stroke risk in atrial fibrillation: A nationwide cohort study (2012) Am J Med, 125, pp. 13-e23. , 826
• Van Walraven, C., Hart, R.G., Connolly, S., Austin, P.C., Mant, J., Hobbs, F.D., Effect of age on stroke prevention therapy in patients with atrial fibrillation (2009) Stroke, 40, pp. 1410-1416
• Olesen, J.B., Lip, G.Y., Hansen, M.L., Hansen, P.R., Tolstrup, J.S., Lindhardsen, J., Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study (2011) BMJ, 342, p. 124
• Potpara, T.S., Polovina, M.M., Licina, M.M., Marinkovic, J.M., Prostran, M.S., Lip, G.Y., Reliable identification of 'truly low' thromboembolic risk in patients initially diagnosed with 'lone' atrial fibrillation: The Belgrade Atrial Fibrillation Study (2012) Circ Arrhythm Electrophysiol, 5, pp. 319-326
• Olesen, J.B., Torp-Pedersen, C., Hansen, M.L., Lip, G., The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study (2012) Thromb Haemost, 107, pp. 1172-1179
• Lip, G.Y., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation (2010) Chest, 137, pp. 263-272
• Independent predictors of stroke in patients with atrial fibrillation: A systematic review (2007) Neurology, 69, pp. 546-554. , Stroke Risk in Atrial Fibrillation Working Group
• Hughes, M., Lip, G.Y.H., Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data (2008) Thrombosis and Haemostasis, 99 (2), pp. 295-304. , http://www.schattauer.de/index.php?id=1871&L=1&no_cache= 1&tx_ivabonnenten_pi5[download]=1&tx_ivabonnenten_pi5[artikel]=22461, DOI 10.1160/TH07-08-0508
• Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials (1998) Arch Intern Med., 158, pp. 1316-1320. , AF-Investigators
• Banerjee, A., Taillandier, S., Olesen, J.B., Lane, D.A., Lallemand, B., Lip, G.Y., Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: The Loire Valley Atrial Fibrillation Project (2012) Eur J Heart Fail, 14, pp. 295-301
• Friberg, L., Benson, L., Rosenqvist, M., Lip, G.Y., Assessment of female sex as a risk factor in atrial fibrillation in Sweden: Nationwide retrospective cohort study (2012) BMJ, 344, p. 3522
• Avgil Tsadok, M., Jackevicius, C.A., Rahme, E., Humphries, K.H., Behlouli, H., Pilote, L., Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation (2012) JAMA, 307, pp. 1952-1958
• Van Staa, T.P., Setakis, E., Di Tanna, G.L., Lane, D.A., Lip, G.Y., A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice (2011) J Thromb Haemost, 9, pp. 39-48
• Abu-Assi E, O., Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation (2011) Int J Cardiol., , Nov 19 [Epub ahead of print]
• Boriani, G., Botto, G.L., Padeletti, L., Santini, M., Capucci, A., Gulizia, M., Italian AT-500 Registry Investigators. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring (2011) Stroke, 42, pp. 1768-1770
• Chao, T.F., Lin, Y.J., Tsao, H.M., Tsai, C.F., Lin, W.S., Chang, S.L., CHADS(2) and CHA(2) DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation (2011) J Am Coll Cardiol, 58, pp. 2380-2385
• Marinigh, R., Lane, D.A., Lip, G.Y., Severe renal impairment and stroke prevention in atrial fibrillation: Implications for thromboprophylaxis and bleeding risk (2011) J Am Coll Cardiol, 57, pp. 1339-1348
• Connolly, S.J., Eikelboom, J.W., Ng, J., Hirsh, J., Yusuf, S., Pogue, J., ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable (2011) Ann Intern Med, 155, pp. 579-586
• Lip, G.Y., Andreotti, F., Fauchier, L., Huber, K., Hylek, E., Knight, E., Bleeding risk assessment, management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis (2011) Europace, 13, pp. 723-746
• Gage, B.F., Yan, Y., Milligan, P.E., Waterman, A.D., Culverhouse, R., Rich, M.W., Radford, M.J., Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF) (2006) American Heart Journal, 151 (3), pp. 713-719. , DOI 10.1016/j.ahj.2005.04.017, PII S0002870305004369
• Pisters, R., Lane, D.A., Nieuwlaat, R., De Vos, C.B., Crijns, H.J., Lip, G.Y., A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey (2010) Chest, 138, pp. 1093-1100
• Fang, M.C., Go, A.S., Chang, Y., Borowsky, L.H., Pomernacki, N.K., Udaltsova, N., A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study (2011) J Am Coll Cardiol, 58, pp. 395-401
• Cairns, J.A., Connolly, S., McMurtry, S., Stephenson, M., Talajic, M., Canadian Cardiovascular Society atrial fibrillation Guidelines 2010: Prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter (2011) Can J Cardiol, 27, pp. 74-90
• Roldan, V., Marin, F., Manzaro-Fernandez, S., Gallego, P., Valdes, M., Vincente, V., Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real world' anticoagulated atrial fibrillation population (2012) Chest., , June 21. doi:10.1378/chest.12-0608
• Apostolakis, S., Lane, D.A., Guo, Y., Buller, H.R., Lip, G.Y.H., Performance of the HEMORR2HAGES, ATRIA and HAS-BLED bleeding risk prediction scores in anticoagulated patients with atrial fibrillation: The AMADEUS study (2012) J Am Coll Cardiol, 60, pp. 861-867
• Lip, G.Y., Frison, L., Halperin, J.L., Lane, D.A., Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) score (2011) J Am Coll Cardiol, 57, pp. 173-180
• Olesen, J.B., Lip, G.Y., Hansen, P.R., Lindhardsen, J., Ahlehoff, O., Andersson, C., Bleeding risk in 'real world' patients with atrial fibrillation: Comparison of two established bleeding prediction schemes in a nationwide cohort (2011) J Thromb Haemost, 9, pp. 1460-1467
• Gallego, P., Roldán, V., Torregrosa, J.M., Gálvez, J., Valdés, M., Vicente, V., Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events and mortality in anticoagulated patients with atrial fibrillation (2012) Circ Arrhythm Electrophysiol, 5, pp. 312-318
• Lane, D.A., Lip, G.Y.H., Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation (2012) Circulation, 126, pp. 860-865
• Friberg, L., Rosenqvist, M., Lip, G., Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the Swedish Atrial Fibrillation cohort study (2012) Circulation, 125, pp. 2298-2307
• Connolly, S.J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M.G., ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range (2008) Circulation, 118, pp. 2029-2037
• Gallagher, A.M., Setakis, E., Plumb, J.M., Clemens, A., Van Staa, T.P., Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients (2011) Thromb Haemost, 106, pp. 968-977
• Wallentin, L., Yusuf, S., Ezekowitz, M.D., Alings, M., Flather, M., Franzosi, M.G., RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial (2010) Lancet, 376, pp. 975-983
• Morgan, C.L., McEwan, P., Tukiendorf, A., Robinson, P.A., Clemens, A., Plumb, J.M., Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control (2009) Thromb Res, 124, pp. 37-41
• Ahrens, I., Lip, G.Y., Peter, K., New oral anticoagulant drugs in cardiovascular disease (2010) Thromb Haemost, 104, pp. 49-60
• Ruff, C.T., Giugliano, R.P., Antman, E.M., Crugnale, S.E., Bocanegra, T., Mercuri, M., Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) (2010) Am Heart J, 160, pp. 635-641
• Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., RE-LY Steering Committee and Investigators. Dabigatran vs. warfarin in patients with atrial fibrillation (2009) N Engl J Med, 361, pp. 1139-1151
• Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Reilly, P.A., Wallentin, L., Newly identified events in the RE-LY trial (2010) N Engl J Med, 363, pp. 1875-1876
• Hohnloser, S.H., Oldgren, J., Yang, S., Wallentin, L., Ezekowitz, M., Reilly, P., Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial (2012) Circulation, 125, pp. 669-676
• Oldgren, J., Alings, M., Darius, H., Diener, H.C., Eikelboom, J., Ezekowitz, M.D., RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the RE-LY trial (2011) Ann Intern Med, 155, pp. 660-667
• Ezekowitz, M.D., Wallentin, L., Connolly, S.J., Parekh, A., Chernick, M.R., Pogue, J., RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation (2010) Circulation, 122, pp. 2246-2253
• Uchino, K., Hernandez, A.V., Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials (2012) Arch Intern Med, 172, pp. 397-402
• Lip, G.Y., Lane, D.A., Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? (2010) Am J Med, 123, pp. 785-789
• Lip, G.Y.H., Larsen, T.B., Skjoth, F., Rasmussen, L.H., Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation (2012) J Am Coll Cardiol, 60, pp. 738-746
• Freeman, J.V., Zhu, R.P., Owens, D.K., Garber, A.M., Hutton, D.W., Go, A.S., Costeffectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation (2011) Ann Intern Med, 154, pp. 1-11
• Sorensen, S.V., Kansal, A.R., Connolly, S., Peng, S., Linnehan, J., Bradley-Kennedy, C., Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective (2011) Thromb Haemost, 105, pp. 908-919
• Pink, J., Lane, S., Pirmohamed, M., Hughes, D.A., Dabigatran etexilate vs. warfarin in management of non-valvular atrial fibrillation in UK context: Quantitative benefit-harm and economic analyses (2011) BMJ, 343, p. 6333
• Shah, S.V., Gage, B.F., Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation (2011) Circulation, 123, pp. 2562-2570
• Banerjee, A., Lane, D.A., Torp-Pedersen, C., Lip, G.Y., Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study (2012) Thromb Haemost, 107, pp. 584-589
• Douxfils, J., Mullier, F., Robert, S., Chatelain, C., Chatelain, B., Dogne, J.M., Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate (2012) Thromb Haemost, 107, pp. 985-997
• Van Ryn, J., Stangier, J., Haertter, S., Liesenfeld, K.H., Wienen, W., Feuring, M., Dabigatran etexilate - A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity (2010) Thromb Haemost, 103, pp. 1116-1127
• Huisman, M.V., Lip, G.Y., Diener, H.C., Brueckmann, M., Van Ryn, J., Clemens, A., Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice (2012) Thromb Haemost, 107, pp. 838-847
• Tripodi, A., Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test? (2011) Thromb Haemost, 105, pp. 735-736
• Barrett, Y.C., Wang, Z., Frost, C., Shenker, A., Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay (2010) Thromb Haemost, 104, pp. 1263-1271
• Pengo, V., Crippa, L., Falanga, A., Finazzi, G., Marongiu, F., Palareti, G., Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) (2011) Thromb Haemost, 106, pp. 868-876
• Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., Meijers, J.C., Buller, H.R., Levi, M., Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects (2011) Circulation, 124, pp. 1573-1579
• Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J.L., Pernod, G., Effect of nonspecific reversal agents on anticoagulant activity of dabigatran, rivaroxaban. A randomised crossover ex vivo study in healthy volunteers (2012) Thromb Haemost, 108, pp. 217-224
• Sié P, S., Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis (2011) Arch Cardiovasc Dis., 104, pp. 669-676
• Omran, H., Bauersachs, R., Rubenacker, S., Goss, F., Hammerstingl, C., The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation (2012) Results from the National Multicentre BNK Online BRiDging REgistRy (BORDER) Thromb Haemost, 108, pp. 65-73
• Nagarakanti, R., Ezekowitz, M.D., Oldgren, J., Yang, S., Chernick, M., Aikens, T.H., Dabigatran vs. warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion (2011) Circulation, 123, pp. 131-136
• Winkle, R.A., Mead, R.H., Engel, G., Kong, M.H., Patrawala, R.A., The use of dabigatran immediately after atrial fibrillation ablation (2011) J Cardiovasc Electrophysiol, 23, pp. 264-268
• Lakkireddy, D., Reddy, Y.M., Di Biase, L., Vanga, S.R., Santangeli, P., Swarup, V., Feasibility and safety of dabigatran vs. warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial Fibrillation results from a multicenter prospective registry (2012) J Am Coll Cardiol, 59, pp. 1168-1174
• Eikelboom, J.W., Wallentin, L., Connolly, S.J., Ezekowitz, M., Healey, J.S., Oldgren, J., Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial (2011) Circulation, 123, pp. 2363-2372
• Ruiz-Nodar, J.M., Marín, F., Roldán, V., Valencia, J., Manzano-Fernández, S., Caballero, L., Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? (2012) Circ Cardiovasc Interv, 5, pp. 459-466
• Lip, G.Y., Huber, K., Andreotti, F., Arnesen, H., Airaksinen, J.K., Cuisset, T., Consensus Document of European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting (2010) Eur Heart J, 31, pp. 1311-1318
• Huber, K., Airaksinen, K.J., Cuisset, T., Marin, F., Rubboli, A., Lip, G.Y., Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe (2011) Thromb Haemost, 106, pp. 569-571
• Faxon, D.P., Eikelboom, J.W., Berger, P.B., Holmes, D.R., Bhatt, D.L., Moliterno, D.J., Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective (2011) Thromb Haemost, 106, pp. 572-584
• Mega, J.L., Braunwald, E., Wiviott, S.D., Bassand, J.P., Bhatt, D.L., Bode, C., A TLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome (2012) N Engl J Med, 366, pp. 9-19
• Alexander, J.H., Lopes, R.D., James, S., Kilaru, R., He, Y., Mohan, P., APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome (2011) N Engl J Med, 365, pp. 699-708
• Matute, M.C., Masjuan, J., Egido, J.A., Fuentes, B., Simal, P., Díaz-Otero, F., Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants (2012) Cerebrovasc Dis, 33, pp. 231-239
• Potpara, T.S., Polovina, M.M., Licina, M.M., Marinkovic, J.M., Prostran, M.S., Lip, G.Y., Reliable identification of 'truly low' thromboembolic risk in patients initially diagnosed with 'lone' atrial fibrillation: The Belgrade Atrial Fibrillation Study (2012) Circ Arrhythm Electrophysiol, 5, pp. 319-326
• Singer, D.E., Chang, Y., Fang, M.C., Borowsky, L.H., Pomernacki, N.K., Udaltsova, N., The net clinical benefit of warfarin anticoagulation in atrial fibrillation (2009) Ann Intern Med, 151, pp. 297-305
• De Caterina, R., Connolly, S.J., Pogue, J., Chrolavicius, S., Budaj, A., Morais, J., Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: Insights from ACTIVE-W (2010) Eur Heart J, 31, pp. 2133-2140
• Hylek, E.M., D'Antonio, J., Evans-Molina, C., Shea, C., Henault, L.E., Regan, S., Translating the results of randomized trials into clinical practice: The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation (2006) Stroke, 37, pp. 1075-1080
• Fox, K.A., Piccini, J.P., Wojdyla, D., Becker, R.C., Halperin, J.L., Nessel, C.C., Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal mpairment (2011) Eur Heart J, 32, pp. 2387-2394
• Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavicius, S., Clopidogrel plus aspirin vs. oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial (2006) Lancet, 367, pp. 1903-1912
• Epstein, A.E., Relationships between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study (2004) Circulation, 109 (12), pp. 1509-1513. , DOI 10.1161/01.CIR.0000121736.16643.11
• Klein, A.L., Grimm, R.A., Murray, R.D., Apperson-Hansen, C., Asinger, R.W., Black, I.W., Davidoff, R., Stoddard, M.F., Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation (2001) New England Journal of Medicine, 344 (19), pp. 1411-1420. , DOI 10.1056/NEJM200105103441901
• Cox, J.L., Cardiac Surgery for Arrhythmias (2004) Journal of Cardiovascular Electrophysiology, 15 (2), pp. 250-262. , DOI 10.1046/j.1540-8167.2004.03656.x
• Bayard, Y.L., Omran, H., Neuzil, P., Thuesen, L., Pichler, M., Rowland, E., PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: Results from the European PLAATO study (2010) EuroIntervention, 6, pp. 220-226
• Park, J.W., Bethencourt, A., Sievert, H., Santoro, G., Meier, B., Walsh, K., Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: Initial European experience (2011) Catheter Cardiovasc Interv, 77, pp. 700-706
• Holmes, D.R., Reddy, V.Y., Turi, Z.G., Doshi, S.K., Sievert, H., Buchbinder, M., Percutaneous closure of the left atrial appendage vs. warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised noninferiority trial (2009) Lancet, 374, pp. 534-542
• Whitlock, R.P., Healey, J.S., Connolly, S.J., Left atrial appendage occlusion does not eliminate the need for warfarin (2009) Circulation, 120, pp. 1927-1932. , discussion, 32
• Dawson, A.G., Asopa, S., Dunning, J., Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? (2010) Interact Cardiovasc Thorac Surg, 10, pp. 306-311
• Reddy, V.Y., Holmes, D., Doshi, S.K., Neuzil, P., Kar, S., Safety of percutaneous left atrial appendage closure: Results from the Watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the Continued Access Registry (2011) Circulation, 123, pp. 417-424
• Roy, D., Rowe, B.H., Stiell, I.G., Coutu, B., Ip, J.H., Phaneuf, D., Lee, J., Beatch, G.N., A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation (2004) Journal of the American College of Cardiology, 44 (12), pp. 2355-2361. , DOI 10.1016/j.jacc.2004.09.021, PII S0735109704018388
• Roy, D., Pratt, C.M., Torp-Pedersen, C., Wyse, D.G., Toft, E., Juul-Moller, S., Nielsen, T., Camm, A.J., Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial (2008) Circulation, 117 (12), pp. 1518-1525. , DOI 10.1161/CIRCULATIONAHA.107.723866, PII 0000301720080325000006
• Pratt, C.M., Roy, D., Torp-Pedersen, C., Wyse, D.G., Toft, E., Juul-Moller, S., Atrial Arrhythmia Conversion Trial (ACT-III) Investigators. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation (2010) Am J Cardiol, 106, pp. 1277-1283
• Kowey, P.R., Dorian, P., Mitchell, L.B., Pratt, C.M., Roy, D., Schwartz, P.J., Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: A randomized, doubleblind, placebo-controlled trial (2009) Circ Arrhythm Electrophysiol, 2, pp. 652-659
• Stiell, I.G., Roos, J.S., Kavanagh, K.M., Dickinson, G., A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm (2010) Am Heart J, 159, pp. 1095-1101
• Camm, A.J., Capucci, A., Hohnloser, S.H., Torp-Pedersen, C., Van Gelder, I.C., Mangal, B., AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation (2011) J Am Coll Cardiol, 57, pp. 313-321
• Briefing Materials for the Cardiovascular and Renal Drugs Advisory Committee December 11, 2007, , FDA Kynapid (vernakalant hydrochloride injection) NDA 22-034. Astellas Pharma US, Inc
• Buccelletti, F., Iacomini, P., Botta, G., Marsiliani, D., Carroccia, A., Gentiloni Silveri, N., Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European Medicines Agency approval: Systematic review and meta-analysis (2011) J Clin Pharmacol., , Dec 13 [Epub ahead of print]
• Bash, L.D., Buono, J.L., Davies, G.M., Martin, A., Fahrbach, K., Phatak, H., Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation (2012) Cardiovasc Drugs Ther, 26, pp. 167-179
• Torp-Pedersen, C., Camm, A.J., Butterfield, N.N., Dickinson, G., Beatch, G.N., Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease (2011) Int J Cardiol., , November 21. doi.org/10.1016/j.ijcard.2011.10.108
• Camm, A.J., Toft, E., Torp-Pedersen, C., Vijayaraman, P., Juul-Moller, S., Ip, J., Scene 2 Investigators. Efficacy and safety of vernakalant in patients (2012) Europace, 14, pp. 804-809
• (2010) E.U. Summary of Product Characteristics, , http://www.ema.europa.eu/docs/en_GB/document_library /EPAR_-_Product_Information/human/001215/WC500097154.pdf, Brinavess, MSD
• Slavik, R.S., Tisdale, J.E., Borzak, S., Pharmacologic conversion of atrial fibrillation: A systematic review of available evidence (2001) Progress in Cardiovascular Diseases, 44 (2), pp. 121-152. , DOI 10.1053/pcad.2001.26966
• Stambler, B.S., Wood, M.A., Ellenbogen, K.A., Perry, K.T., Wakefield, L.K., Vanderlugt, J.T., Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation (1996) Circulation, 94, pp. 1613-2152
• Volgman, A.S., Carberry, P.A., Stambler, B., Lewis, W.R., Dunn, G.H., Perry, K.T., Vanderlugt, J.T., Kowey, P.R., Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation (1998) Journal of the American College of Cardiology, 31 (6), pp. 1414-1419. , DOI 10.1016/S0735-1097(98)00078-3, PII S0735109798000783
• Vos, M.A., Golitsyn, S.R., Stangl, K., Ruda, M.Y., Van Wijk, L., Harry, J.D., Perry, K.T., Wellens, H.J.J., Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation (1998) Heart, 79 (6), pp. 568-575
• Savelieva, I., Kakouros, N., Kourliouros, A., Camm, A.J., Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology Guidelines. Part I: Primary prevention (2011) Europace, 13, pp. 308-328
• Savelieva, I., Kakouros, N., Kourliouros, A., Camm, A.J., Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology Guidelines. Part II: Secondary prevention (2011) Europace, 13, pp. 610-625
• Goette, A., Schön, N., Kirchhof, P., Breithardt, G., Fetsch, T., Häusler, K.G., Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial (2012) Circ Arrhythm Electrophysiol, 5, pp. 43-51
• Yamashita, T., Inoue, H., Okumura, K., Kodama, I., Aizawa, Y., Atarashi, H., J-RHYTHM II Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study) (2011) Europace, 13, pp. 473-479
• Bianconi, L., Calò, L., Mennuni, M., Santini, L., Morosetti, P., Azzolini, P., N-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: A randomized, double-blind, multicentre study (2011) Europace, 13, pp. 174-181
• Kowey, P.R., Reiffel, J.A., Ellenbogen, K.A., Naccarelli, G.V., Pratt, C.M., Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: A randomized controlled trial (2010) JAMA, 304, pp. 2363-2372
• Lafuente-Lafuente, C., Mouly, S., Longas-Tejero, M.A., Mahe, I., Bergmann, J.F., Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: A systematic review of randomized controlled trials (2006) Arch Intern Med, 166, pp. 719-728
• Freemantle, N., Lafuente-Lafuente, C., Mitchell, S., Eckert, L., Reynolds, M., Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation (2011) Europace, 13, pp. 329-345
• Piccini, J.P., Hasselblad, V., Peterson, E.D., Washam, J.B., Califf, R.M., Kong, D.F., Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation (2009) J Am Coll Cardiol, 54, pp. 1089-1095
• Sullivan, S.D., Orme, M.E., Morais, E., Mitchell, S.A., Interventions for the treatment of atrial fibrillation: A systematic literature review and meta-analysis (2012) Int J Cardiol., , March 31. doi.org/10.1016/j.ijcard.2012.03.070
• Kirchhof, P., Andresen, D., Bosch, R., Borggrefe, M., Meinertz, T., Parade, U., Shortterm versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial (2012) Lancet, 380, pp. 238-246
• Ahmed, S., Rienstra, M., Crijns, H.J., Links, T.P., Wiesfeld, A.C., Hillege, H.L., CONVERT Investigators. Continuous vs. episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: A randomized trial (2008) JAMA, 300, pp. 1784-1792
• Connolly, S.J., Evidence-based analysis of amiodarone efficacy and safety (1999) Circulation, 100 (19), pp. 2025-2034
• Hohnloser, S.H., Crijns, H.J., Van Eickels, M., Gaudin, C., Page, R.L., Torp-Pedersen, C., ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation (2009) N Engl J Med, 360, pp. 668-678
• Kober, L., Torp-Pedersen, C., McMurray, J.J.V., Gotzsche, O., Levy, S., Crijns, H., Amlie, J., Carlsen, J., Increased mortality after dronedarone therapy for severe heart failure (2008) New England Journal of Medicine, 358 (25), pp. 2678-2687. , http://content.nejm.org/cgi/reprint/358/25/2678.pdf, DOI 10.1056/NEJMoa0800456
• Duray, G.Z., Schmitt, J., Hohnloser, S.H., Dronedarone therapy in atrial fibrillation: A summary of recent controlled trials (2010) J Cardiovasc Pharmacol Ther, 15 (SUPPL. 4), pp. 19-S23
• Camm, A.J., Savelieva, I., Atrial fibrillation: The rate vs. rhythm management controversy (2012) J R Coll Physicians Edinb, 42 (SUPPL. 18), pp. 23-34
• Touboul, P., Brugada, J., Capucci, A., Crijns, H.J.G.M., Edvardsson, N., Hohnloser, S.H., Dronedarone for prevention of atrial fibrillation: A dose-ranging study (2003) European Heart Journal, 24 (16), pp. 1481-1487. , DOI 10.1016/S0195-668X(03)00321-X
• Singh, B.N., Connolly, S.J., Crijns, H.J.G.M., Roy, D., Kowey, P.R., Capucci, A., Radzik, D., Hohnloser, S.H., Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter (2007) New England Journal of Medicine, 357 (10), pp. 987-999. , http://content.nejm.org/cgi/reprint/357/10/987.pdf, DOI 10.1056/NEJMoa054686
• Davy, J.M., Herold, M., Hoglund, C., Timmermans, A., Alings, A., Radzik, D., Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study (2008) Am Heart J, 156, p. 527. , e1-9
• Le Heuzey, J.Y., De Ferrari, G.M., Radzik, D., Santini, M., Zhu, J., Davy, J.M., A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone vs. amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study (2010) J Cardiovasc Electrophysiol, 21, pp. 597-605
• Cosedis Nielsen, J., Johannessen, A., Raatikainen, P., Hindricks, G., Walfridsson, H., Kongstad, O., A randomized comparison of radiofrequency ablation and antiarrhythmia drug therapy as first line treatment in paroxysmal atrial fibrillation (2012) N Engl J Med., , en prensa
• Morillo, C., Verma, A., Kuck, K.H., Radiofrequency Ablation vs. Antiarrhythmic Drugs as First-Line Treatment of Symptomatic Atrial Fibrillation: (RAAFT 2): A randomized trial (2012) Heart Rhythm Society 2012 Scientific Sessions, , May 11
• Boston, Massachusetts, Estados Unidos. Abstract LB02-1
• Wazni, O.M., Marrouche, N.F., Martin, D.O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Natale, A., Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial (2005) Journal of the American Medical Association, 293 (21), pp. 2634-2640. , DOI 10.1001/jama.293.21.2634
• Boersma, L.V., Castella, M., Van Boven, W., Berruezo, A., Yilmaz, A., Nadal, M., Atrial fibrillation catheter ablation vs. surgical ablation treatment (FAST): A 2-center randomized clinical trial (2012) Circulation, 125, pp. 23-30
• Pison, L., La Meir, M., Van Opstal, J., Blaauw, Y., Maessen, J., Crijns, H.J., Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation (2012) J Am Coll Cardiol, 60, pp. 54-61
• Weerasooriya, R., Khairy, P., Litalien, J., MacLe, L., Hocini, M., Sacher, F., Catheter ablation for atrial fibrillation: Are results maintained at 5 years of follow-up? (2011) J Am Coll Cardiol, 57, pp. 160-166
• Ouyang, F., Tilz, R., Chun, J., Schmidt, B., Wissner, E., Zerm, T., Long-term results of catheter ablation in paroxysmal atrial fibrillation: Lessons from a 5-year followup (2010) Circulation, 122, pp. 2368-2377
• Tzou, W.S., Marchlinski, F.E., Zado, E.S., Lin, D., Dixit, S., Callans, D.J., Long-term outcome after successful catheter ablation of atrial fibrillation (2010) Circ Arrhythm Electrophysiol, 3, pp. 237-242
• Arya, A., Hindricks, G., Sommer, P., Huo, Y., Bollmann, A., Gaspar, T., Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients (2010) Europace, 12, pp. 173-180
• Oral, H., Knight, B.P., Ozaydn, M., Tada, H., Chugh, A., Hassan, S., Scharf, C., Morady, F., Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation (2002) Journal of the American College of Cardiology, 40 (1), pp. 100-104. , DOI 10.1016/S0735-1097(02)01939-3, PII S0735109702019393
• Lellouche, N., Jais, P., Nault, I., Wright, M., Bevilacqua, M., Knecht, S., Matsuo, S., Haissaguerre, M., Early recurrences after atrial fibrillation ablation: Prognostic value and effect of early reablation (2008) Journal of Cardiovascular Electrophysiology, 19 (6), pp. 599-605. , DOI 10.1111/j.1540-8167.2008.01188.x
• Pokushalov, E., Romanov, A., Corbucci, G., Bairamova, S., Losik, D., Turov, A., Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up? (2012) Heart Rhythm., , March 23. doi.org/10.1016/j.hrthm.2012.03.047
• Medi, C., Sparks, P.B., Morton, J.B., Kistler, P.M., Halloran, K., Rosso, R., Pulmonary vein antral isolation for paroxysmal atrial fibrillation: Results from long-term follow-up (2011) J Cardiovasc Electrophysiol, 22, pp. 137-141
• Lee, G., Sparks, P.B., Morton, J.B., Kistler, P.M., Vohra, J.K., Medi, C., Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: Results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center (2011) J Cardiovasc Electrophysiol, 22, pp. 163-168
• Arbelo, E., Brugada, J., Hindricks, G., Maggioni, A., Tavazzi, L., Vardas, P., On behalf of the Atrial Fibrillation Ablation Pilot Study Investigators. ESC-EURObservational research programme: The atrial fibrillation ablation pilot study, conducted by the European Heart Rhythm Association (2012) Europace, 14, pp. 1094-1103
• Hoyt, H., Bhonsale, A., Chilukuri, K., Alhumaid, F., Needleman, M., Edwards, D., Complications arising from catheter ablation of atrial fibrillation: Temporal trends and predictors (2011) Heart Rhythm, 8, pp. 1869-1874
• Cappato, R., Calkins, H., Chen, S.A., Davies, W., Iesaka, Y., Kalman, J., Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation (2010) Circ Arrhythm Electrophysiol, 3, pp. 32-38
• Shah, R.U., Freeman, J.V., Shilane, D., Wang, P.J., Go, A.S., Hlatky, M.A., Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation (2012) J Am Coll Cardiol, 59, pp. 143-149
• Herrera Siklódy, C., Deneke, T., Hocini, M., Lehrmann, H., Shin, D.I., Miyazaki, S., Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: Comparison of different atrial fibrillation ablation technologies in a multicenter study (2011) J Am Coll Cardiol, 58, pp. 681-688
• Di Biase, L., Burkhardt, J.D., Mohanty, P., Sanchez, J., Horton, R., Gallinghouse, G.J., Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio (2010) Circulation, 121, pp. 2550-2556
• Haeusler, K.G., Kirchhof, P., Endres, M., Left atrial catheter ablation and ischemic stroke (2012) Stroke, 43, pp. 265-270
• Gaita, F., Leclercq, J.F., Schumacher, B., Scaglione, M., Toso, E., Halimi, F., Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: Comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon (2011) J Cardiovasc Electrophysiol, 22, pp. 961-968
• Kirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., Camm, A.J., Cappato, R., Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation' (2009) Europace, 11, pp. 860-885
• Van Gelder, I.C., Haegeli, L.M., Brandes, A., Heidbuchel, H., Aliot, E., Kautzner, J., Rationale and current perspective for early rhythm control therapy in atrial fibrillation (2011) Europace, 13, pp. 1517-1525
• Schmidt, M., Segerson, N.M., Marschang, H., Akoum, N., Rittger, H., Clifford, S.M., Atrial fibrillation ablation in patients with therapeutic international normalized ratios (2009) Pacing Clin Electrophysiol, 32, pp. 995-999
• Page, S.P., Siddiqui, M.S., Finlay, M., Hunter, R.J., Abrams, D.J., Dhinoja, M., Catheter ablation for atrial fibrillation on uninterrupted warfarin: Can it be done without echo guidance? (2011) J Cardiovasc Electrophysiol, 22, pp. 265-270
• Gautam, S., John, R.M., Stevenson, W.G., Jain, R., Epstein, L.M., Tedrow, U., Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation (2011) J Cardiovasc Electrophysiol, 22, pp. 248-254
• Gopinath, D., Lewis, W.R., Di Biase, L., Natale, A., Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: Special considerations (2011) J Cardiovasc Electrophysiol, 22, pp. 236-239
• Hakalahti, A., Uusimaa, P., Ylitalo, K., Raatikainen, M.J., Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment (2011) Europace, 13, pp. 640-645
• Latchamsetty, R., Gautam, S., Bhakta, D., Chugh, A., John, R.M., Epstein, L.M., Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin (2011) Heart Rhythm, 8, pp. 805-808
• Calkins, H., Kuck, K.H., Cappato, R., Brugada, J., Camm, A.J., Chen, S.A., 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design (2012) Europace, 14, pp. 528-606
• Kirchhof, P., Lip, G.Y., Van Gelder, I.C., Bax, J., Hylek, E., Kaab, S., Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options - A report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference (2012) Europace, 14, pp. 8-27
• Van Gelder, I.C., Haegeli, L.M., Brandes, A., Heidbuchel, H., Aliot, E., Kautzner, J., Rationale and current perspective for early rhythm control therapy in atrial fibrillation (2011) Europace, 13, pp. 1517-1525
• Pappone, C., Vicedomini, G., Augello, G., Manguso, F., Saviano, M., Baldi, M., Radiofrequency catheter ablation and antiarrhythmic drug therapy: A prospective, randomized, 4-year follow-up trial: The APAF study (2011) Circ Arrhythm Electrophysiol, 4, pp. 808-814
• Tanner, H., Makowski, K., Roten, L., Seiler, J., Schwick, N., Müller, C., Complications arising from catheter ablation of atrial fibrillation: Temporal trends and predictors (2011) Europace, 13, pp. 646-653
• Wazni, O., Wilkoff, B., Saliba, W., Catheter ablation for atrial fibrillation (2011) N Engl J Med, 365, pp. 2296-2304
• Calkins, H., Reynolds, M.R., Spector, P., Sondhi, M., Xu, Y., Martin, A., Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: Two systematic literature reviews and meta-analyses (2009) Circ Arrhythm Electrophysiol, 2, pp. 349-361
• Wilber, D.J., Pappone, C., Neuzil, P., De Paola, A., Marchlinski, F., Natale, A., ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial (2010) JAMA, 303, pp. 333-340
• Haissaguerre, M., Jais, P., Shah, D.C., Takahashi, A., Hocini, M., Quiniou, G., Garrigue, S., Clementy, J., Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins (1998) New England Journal of Medicine, 339 (10), pp. 659-666. , DOI 10.1056/NEJM199809033391003
• Leong-Sit, P., Roux, J.F., Zado, E., Callans, D.J., Garcia, F., Lin, D., Antiarrhythmics after ablation of atrial fibrillation (5A Study): Six-month follow-up study (2011) Circ Arrhythm Electrophysiol, 4, pp. 11-14